Bhanvi Satija
路透7月18日 - 一位熟悉内情的消息人士周五告诉路透，美国食品和药物管理局将要求Sarepta Therapeutics SRPT.O自愿停止其基因疗法Elevidys的所有发货。
Elevidys是一种在美国获批用于治疗肌肉萎缩性疾病杜氏肌营养不良症的基因疗法。
这两名男孩都是不能行走的患者，或者说是不能独立行走的患者，Sarepta 公司已于今年 6 月停止向这一患者群体供应该疗法。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.